Pharmacy

FDA’s plan to evaluate gene therapies’ impact on surrogate end points is amping up concerns among payers. Here’s why

Trust in the healthcare sector is dropping, a warning sign to executives. Here’s four ways how to reclaim it.

To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive conducted its annual pharmacy survey during the first quarter of 2018.  

Healthcare experts weigh in on the president’s plan to lower drug prices. Here’s what they said.

A Quest Diagnostics study sheds light on Medicare patients with multiple chronic conditions and the top three care gaps.

Legislation removes FDA involvement when patients seek experimental medications. Here’s what critics and proponents say.

Congress recently began hearings on proposals to combat opioid abuse. Our policy analyst weighs in.

Experts say this new migraine medication, the first in 50 years, shows great promise. Here’s what you need to know, including the cost implications

A new survey from Express Scripts has surprisingly findings about medication adherence in patients with chronic diseases.

A new study sheds light on PDMPs and their effectiveness in tackling the opioid crisis and includes one disturbing finding you won’t believe.

A new study investigates the impact of interruptions in the emergency room. Here are the disturbing results

The new Bipartisan Budget Act of 2018, to be in effect on January 2019, institutes new reimbursement guidelines for biosimilars under the Medicare coverage gap discount program that remove disincentives for biosimilar uptake and level the playing field for the future market place.

How skipping industry acronyms and jargon and using simple terminology will eliminate confusion and misinterpretation.

A Surescripts survey reveals the need for more interoperable access to patient data in three major areas.

An ONC report finds that more patients are engaged with their health records. Here’s why.

The goal is to help ensure that prescription drug marketing information for consumers and healthcare providers is truthful and balanced. Here’s what the agency plans to research.

Drug makers and payers have these challenges to implement outcomes-based contracts, but here are three steps that can be taken as a transition toward these payment arrangements.

A new report is making some healthcare executives a bit more optimistic about efforts to curb the opioid epidemic. Find out why.

A new program shows promise for improving patient medication adherence. Find out how it works.